Hematopoiesis News Volume 7.20 | May 24 2016

Vascular Control of the Drosophila Hematopoietic Microenvironment by Slit/Robo Signaling
Researchers revealed that signals from the vascular system contribute to regulating the rate of blood cell differentiation via the regulation of posterior signaling center morphology. [Nat Commun] Full Article

Graphene Oxide Promotes Embryonic Stem Cell Differentiation to Hematopoietic Lineage
Investigators demonstrated that graphene oxide coated substrates significantly enhance the differentiation of mouse embryonic stem cells to both primitive and definitive hematopoietic cells. [Sci Rep] Full Article

Small Molecule Activation of NOTCH Signaling Inhibits Acute Myeloid Leukemia
Scientists report N-methylhemeanthidine chloride not only selectively inhibits acute myeloid leukemia (AML) cell proliferation in vitro but also hampers tumor development in a human AML xenograft model. [Sci Rep] Full Article

Pten Cell Autonomously Modulates the Hematopoietic Stem Cell Response to Inflammatory Cytokines
Investigators sought to clarify whether Pten cell autonomously or non-cell autonomously regulates hematopoietic stem cells (HSCs) mobilization. They also tested whether Pten deficiency affects the HSC response to granulocyte colony-stimulating factor and interferon-α since these cytokines induce HSC mobilization or proliferation, respectively. [Stem Cell Reports] Full Article | Graphical Abstract

Trib2 Suppresses Tumor Initiation in Notch-Driven T-ALL
The authors investigated the role of Trib2 in the initiation and maintenance of Notch-dependent T cell acute lymphoblastic leukemia (T-ALL). Trib2 had no effect on the growth and survival of murine T-ALL cell lines in vitro when expression was blocked by shRNAs. [PLoS One] Full Article

CLINICAL RESEARCH

KPT-8602, a Second-Generation Inhibitor of XPO1-Mediated Nuclear Export, Is Well Tolerated and Highly Active against AML Blasts and Leukemia-Initiating Cells
Scientists report the anti-leukemic efficacy and tolerability of KPT-8602, a second-generation XPO1 inhibitor. KPT-8602 demonstrated substantially reduced brain penetration compared to selinexor, with resultant attenuation of the CNS-mediated side effects of anorexia and weight loss. [Leukemia] Full Article

Bendamustine, Etoposide and Dexamethasone to Mobilize Peripheral Blood Hematopoietic Stem Cells for Autologous Transplantation in Patients with Multiple Myeloma
The authors performed a prospective, nonrandomized Phase II study including 34 patients with multiple myeloma (MM) to evaluate bendamustine’s efficacy and safety as a stem cell mobilizing agent. [Bone Marrow Transplant] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

From our sponsor: Learn about applications of ALDHbr cells in regenerative medicine. Watch the video.

Janssen’s Single-Agent DARZALEX^® (Daratumumab) Approved by European Commission for Treatment of Multiple Myeloma (MM)
Janssen-Cilag International NV announced that the European Commission has granted conditional approval to DARZALEX^® for monotherapy of adult patients with relapsed and refractory MM, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. [Janssen-Cilag International NV] Press Release

Opdivo^® (Nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA1
Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration (FDA) has approved Opdivo^® for the treatment of patients with classical Hodgkin lymphoma who have relapsed or progressed after autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation brentuximab vedotin. [Bristol-Myers Squibb Company (Business Wire)] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis community.

Scientific Communications and Publishing Coordinator (STEMCELL Technologies Inc.)

Technical Sales Representative (STEMCELL Technologies Inc.)

Scientist – Hematology (STEMCELL Technologies Inc.)

Postdoctoral Research Associate – Myeloid Leukemia (Upstate Medical University)

Postdoctoral Fellow – Leukemia Lymphoma (Emory University)

Postdoctoral Scientist – Mouse Hematopoiesis (Lund University)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology and Blood Disorders (Brigham & Women’s Hospital)

Research Technician – Hematopoietic Stem Cell Biology (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Associate – Stem Cell Aging Biology (University of Southern California)

Postdoctoral Fellow – Hematopoietic Stem Cells (University of Pennsylvania)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.